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Abstract
Objective: Glutathione-S-transferase (GSt) subtype a
and p are differentially expressed in adult liver tissue.
objective of the study was if GSt a and p may serve
as predictive markers for liver surgery, especially trans-
plantations. 
Methods: 13 patients receiving living donor liver trans-
plantation  (ldlt)  and  their  corresponding  donors
were  analyzed  for  standard  serum  parameters  (alt,
aSt, gGt, bilirubin) as well as GSt-a and -p before
ldlt and daily for 10 days after ldlt. Patients (R)
and donors (d) were grouped according to graft loss
(R1/d1)  or  positive  outcome  (R2/d2)  and  above
named serum parameters were compared between the
groups.
Results: R1 showed significantly increased GSt-a and
significantly lower GSt-p levels than R2 patients or
the donors. there was a positive correlation between
GSt-a and alt, aSt as well as bilirubin and a nega-
tive correlation to gGt. However, gGt correlated pos-
itively with GSt-p. Graft failure was associated with
combined low GSt-p levels in donors and their recipi-
ents before living donor liver transplantation. 
Conclusion: our data suggest that high GSt-a serum
levels reflect ongoing liver damage while GSt-p indi-
cates the capacity and process of liver regeneration.
additionally, GSt-p may be useful as marker for opti-
mizing donor and recipient pairs in living donor liver
transplantation.
Key words: living donor liver transplantation, liver re-
generation, glutathione-S-transferase a and p, chole  -
stasis
Abbreviations:  d,  donor  group;  d1,  donors  corre-
sponding to recipients with liver failure; d2, donors
corresponding  to  recipients  with  positive  outcome;
GSt-a, glutathione-S-transferase-alpha; GSt-p, gluta  -
thione-S-transferase-pi;  ldlt,  living  donor  liver
transplantation; Pod, post operative day; R, recipient
group; R1, recipients with liver failure; R2, recipients
with positive outcome.
IntRoductIon
living donor liver transplantation (ldlt) has become
an alternative to deceased donor liver transplantation
in  the  western  countries  to  overcome  the  perpetual
shortage of donor organs. the unique ability of the
liver  to  regenerate  completely  after  resection  makes
this approach possible. Remarkably, the liver volume
restoration occurs within four weeks after ldlt in
the vast majority of both donors and recipients [1, 2,
3-5]. However, in some cases the transplanted liver ex-
hibits impaired regeneration, which consequently leads
to liver failure [6]. therefore, it remains a challenge to
identify those livers with and without sufficient capaci-
ty to regenerate after ldlt or partial hepatectomy.
Recently, it has been shown in a rat model of cir-
rhosis and regeneration that the enzyme glutathione-s-
transferase (GSt) and their predominant hepatic sub-
types show a distinct pattern during regeneration [7].
In  general,  GSt  comprises  various  subtypes  of  en-
zymes, catalyzing the binding of glutathione to xeno-
biotics, thus facilitating their detoxification. up to 3%
of soluble protein in adult hepatocytes constitutes of
GSt subtype alpha (GSt-a), while GSt subtype pi
(GSt-p) is expressed in fetal hepatocytes and in the
placenta [8]. Expression of GSt-p in adult liver tissue
is restricted to bile duct cells and constitutes a pheno-
typic marker of oval cells [9]. oval cells represent a
bipotent population of progenitor cells, which can dif-
ferentiate into hepatocytes and biliary epithelial cells
[10, 11]. these cells are involved in liver regeneration
following severe liver injury and in liver carcinogenesis
[12, 9]. different studies in animal models of partial
hepatectomy identified GSt-p expression in oval cells
as relevant for liver regeneration [13, 14, 15]. However,
the regulation of oval cell recruitment and differentia-
tion as well as their precise role remains unclear.
GSt  enzymes  are  intracellular  cytosolic  enzymes.
thus, GSt serum levels rather than protein expression
reflect  cell  injury  or  cell  turnover.  the  half-life  of
GSt  is  short  (<90  min.)  (6),  therefore  changes  in
GSt-levels closely match ongoing liver cell death. In-
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6) Jochum_Umbruchvorlage  14.01.11  12:09  Seite 34deed, in acute liver failure GSt-a is highly elevated
and  is  associated  with  worse  outcome  (unpublished
data). GSt-a levels are also significantly elevated in
liver  transplant  recipients  who  develop  moderate  or
severe rejection after liver transplantation compared to
those recipients with mild or no rejection [16]. In con-
trast, GSt-p levels remain stable even in cases of se-
vere rejection, suggesting both enzymes are restricted
to different cell types and play independent roles in
organ rejection [16] . apart from this high expression
levels of GSt-p were seen in patients with liver cir-
rhosis and chronic hepatitis [17].
the  aim  of  our  study  was  to  determine  whether
serum GSt-a and GSt-p levels are related to liver re-
generation after ldlt in donors and recipients. to
check this we proposed several questions: i) are GSt-
a and GSt-p differentially released into the serum in
donors and recipients before or after ldlt? ii) are
increased  GSt-a levels  associated  with  transplant
loss? and finally (iii) are lower GSt-p levels associated
with impaired liver regeneration?
to study these questions donors and recipients in
ldlt were compared for GSt serum levels and out-
come. furthermore donors and recipients each were
split into two sub-groups, donors and corresponding
recipients with transplant loss, due to vascular compli-
cations, occurring in the early postoperative period (4
weeks) were subsequently labeled as d1 and R1. Re-
cipients who recovered uneventfully and correspond-
ing donors were labeled as R2 and d2, respectively. 
MatERIal and MEtHodS
cHaRactERIStIcS of PatIEntS and donoRS
In this study 13 consecutive living donors of a right
liver lobe (segment 5-8) and their recipients were in-
cluded.  all  patients  provided  informed  consent.  all
donors were healthy and eligible for ldlt following
the  guidelines  for  selection  of  living  related  liver
donors at the university of Essen (Germany). demo-
graphics of donors and recipients as well as the indica-
tions for ldlt are summarized in table 1. the recipi-
ents received between 54.7 and 66.4% of the donor’s
liver volume (median: 60.6%; mean: 60.4%).  four re-
cipients required retransplantation due to organ failure
within the first 4 weeks after transplantation, thus con-
stituting  group  R1  with  the  respective  donor  group
d1. Groups R2 and d2 included the remaining 9 re-
cipients and donors with positive outcome .
laboRatoRy data
Serum and plasma samples of donors and recipients
were obtained as a baseline (Pod 0) three days to six
weeks prior to the transplantation. Serum and plasma
samples were obtained daily (7.30 am ﾱ 15 min) from
Pod 1 to 10. the plasma samples were immediately
stored on ice, centrifuged and stored at –20ﾰc. biliru-
bin, aSt, alt and gGt were determined at the cen-
tral laboratory of the university of Essen.
the  concentrations  of  GSt-a and  GSt-p were
measured  using  commercially  available  ElISa-Kits
(biotrin  International  GmbH,  dreieich,  Germany).
the  concentrations  of  GSt-a were  determined  in
serum and concentrations of GSt-p in plasma. the
internal controls were within the sensitivity of the test. 
data analySES and StatIStIcS
all data are shown as mean ﾱ SEM, if not stated oth-
erwise. the data were analyzed for day to day changes
and  for  the  time  course  after  ldlt.  for  statistical
analyses a two-sided t-test for unrelated groups was
used. Statistical significance was assumed for p < 0.05.
calculations were done using GraphPad Prism‘ Soft-
ware.  correlations  were  calculated  using  SPSS  Soft-
ware, employing non-parametric tests (Spearman rank
correlation).
RESultS
There are no significant differences in GST-a lev-
els between donors and recipients before LDLT.
Previous to ldlt (Pod 0) higher average values of
GSt-a were found in donors than in recipients (6.4
vs. 4.98ﾵg/ml). both remained in the normal range of
<7.2 ﾵg/ml and the differences were not significant p
= 0.37 (fig. 1a). additionally neither R1 vs. R2 nor
d1 vs. d2 showed any differences at Pod 0. 
Graft loss is associated with higher GST-a lev-
el. at Pod 1, the mean serum levels of GSt-a in-
creased  significantly  in  both  donors  and  recipients 
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Table 1. Patient characteristics: two recipients with toxic cirrhosis were also infected with Hepatitis c virus. 6 recipients had a
Hcc in the cirrhotic liver. (abbr.: Hcc= hepatocellular carcinoma; PSc= primarily sclerosing cholangitis).
Parameter Donors Recipients
age 23-59 ys; median 30ys 26-65ys; median 50ys
Male 78
female 65
(Ethyl-)toxic cirrhosis -6
Hepatitis c -2
Hepatitis b -2
Hcc -6
PSc -1
autoimmune Hepatitis -1
cryptogenic cirrhosis -3
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stronger in recipients during the post-transplantation
period compared to donors (p = 0.04). over the fol-
lowing days GSt-a serum values decreased in donors
and recipients, reaching preoperative values in donors
at Pod 4 and in recipients at Pod 5. R1 patients ex-
hibited  significantly  higher  serum  levels  of  GSt-a
than the R2 group (p = 0.002; fig. 1b) and all donors
(p = 0.003) in the observed post transplantation phase.
In contrast the time course in R2 patients compared to
all donors did not display significant differences and
GSt-a levels reached preoperative values after Pod 4
as did both donor groups. 
Lower plasma GST-p in donors and recipients
before  LDLT  is  associated  with  graft  loss. at
Pod 0 donor and recipient GSt-p levels were on av-
erage  quite  similar  (donors:  65.4  ng/ml;  recipients:
67.4 ng/ml; fig. 2a), on the contrary subgroup analy-
sis demonstrated differences. R1- and d1-individuals
showed significantly lower GSt-p values than R2- and
d2-individuals at Pod 0 (fig. 2b, c). analysis of the
individual donor-recipient pairs revealed GSt-p values
below 50ng/ml in both, donor and corresponding re-
cipient, in pairs where graft loss occurred (fig. 2d).
conversely,  in  cases  with  positive  outcome  plasma
GSt-p was high in donor and/or recipient. the GSt-
p levels increased in all donors after resection and re-
mained  elevated  through  Pod  10,  although  with  a
broad variance. after transplantation in both recipient
groups  significantly  lower  GSt-p levels  were  found
than in the donors (p = 0.00001). Subgroup R1 dis-
played  significantly  lower  GSt-p values  during  the
postoperative  period  compared  to  R2  or  all  donors 
(p =  0.001;  p =  4.7x10-8).  Interestingly,  the  R2-pa-
tients also were found to have significantly lower GSt-
p levels than the donors (p = 0.003).
There are no significant differences in conven-
tional liver function tests between donors and re-
cipients in the early phase after LDLT. aSt and
alt levels were significantly increased on Pod 0 in
recipients compared to donors (fig. 3). donors as well
as recipients exhibited a short term increase of aSt
and alt after transplantation but both enzymes de-
creased over time back to normal levels. the observed
increase in aSt and alt was more articulate in groups
d1 and R1 in comparison to d2 and R2, respectively,
although the differences failed to reach significance.
gGt  was  significantly  elevated  in  recipients  com-
pared to donors on Pod 0. from Pod 1 to Pod 4
gGt in recipients decreased but was still significantly
higher than in donors. after Pod 5 the serum levels
raised in both donors and recipients, though the in-
crease was more prominent in recipients. In d1 and
d2 no differences in the serum gGt were found, stay-
ing low until Pod 4, with a constant rise detectable
from Pod 5 to Pod 10. a similar time course was
found in the R2 group, with a raise of serum gGt to-
ward the end of the observation period (Pod 5 to
10). R1 patients did not exhibit a comparable pattern,
but stayed at low gGt values.
Preoperative bilirubin levels were significantly ele-
vated in recipients referring to donors. Serum bilirubin
constantly increased during Pod 1 to 4 and regressed
to normal levels until Pod10. a similar pattern was
observable in d1 and d2, although d2 patients had
slightly higher serum values. Recipients displayed a re-
duction of bilirubin in serum on Pod 2, slowly re-
turning to raised preoperative levels from Pod 3 to
Pod 8. While R1 bilirubin was significantly reduced
compared to R2 on Pod 0, no significant differences
between these groups were detected after transplanta-
tion.
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Fig. 1. GSt-a in donors and Recipients.  Shown are average serum GSt-a
values with SEM during 10 days after transplantation, with a single pre opera-
tive sample as reference (Pod 0). a: time course of all donors and recipients.
b: d1 = donors of patients with graft loss; d2 = donors of patients with ben-
eficial outcome. c: R1 = recipients who suffered from graft loss within 4 weeks
after ldlt.; R2 = recipients with positive outcome.
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Fig. 2. GSt-p in donors and Recipients. average plasma GSt-p values with SEM during 10 days after transplanta-
tion. as reference a single pre operative time point (Pod0) was used. a: time course of all donors and recipients.
b: d1 = donors of patients with graft loss; d2 = donors of patients with beneficial outcome. c: R1 = recipients
who suffered from graft loss within 4 weeks p.o.; R2 = recipients with positive outcome. d: GSt-p values before
ldlt of individual donor and recipient pairs. black dots represent donors and recipients of group 1, white dots
those of group 2. *: p<0.05; **p<0.01.
Fig. 3. liver function Parameters in donors and Recipients. time courses of standard serum parameters for liver damage for
donors and recipients and the subgroups d1, d2, R1 and R2. a: alt; b: aSt; c: bilirubin; d: gGt; *: p<0.05.
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and negatively with GST-a. non-parametric corre-
lation  analyses  of  GSt-a and  GSt-p,  respectively,
with the established serum parameters aSt, alt, gGt
and bilirubin were conducted for donors and recipi-
ents (table 2). GSt-p correlated significantly positive
with gGt in recipients and donors (R: 0.307, p<0.001;
d: 0.212, p=0.017). In contrast, GSt-a was signifi-
cantly negatively correlated with gGt in recipients (-
0.33,  p<0.001)  and  positively  correlated  with  alt,
aSt and bilirubin in recipients and donors.
dIScuSSIon
liver regeneration in different settings, for example in
partial hepatectomy, acute liver failure, and in living re-
lated  liver  transplantation  (ldlt),  respectively,  is  a
major issue in hepatology. despite quick recovery of
liver volume [5]  qualitative regeneration takes longer
and  might  influence  the  outcome  of  ldlt  [4,  18]
Predictive markers, obtainable in a non invasive fash-
ion, are warranted to estimate chances of patients to
appropriately regenerate after liver surgery. Patient sur-
vival on the one hand and liver failure after transplan-
tation on the other hand could be improved by reliable
indicators of expected regeneration.
Glutathione-s-transferase (GSt) might serve as an
early marker in liver regeneration.  Indeed, GSt-a lev-
els peaked at Pod 1 both in donors and recipients
with a decline over the following days. Highest GSt-a
values were found in those recipients who lost their
grafts (R1) during the postoperative period, suggesting
increased hepatocyte death and liver function impair-
ment. Serum levels in R1-patients were significantly el-
evated  compared  to  donors  and  the  R2-group.  of
note, there were no significant differences in GSt-a
levels between donors and R2-individuals. these find-
ings suggest increased GSt-a as a possibly useful indi-
cator for poor outcome and eventual graft loss and are
consistent with data from deceased donor liver trans-
plantations [16]. additionally, GSt-a showed positive
correlation  to  alt  and  aSt  and  bilirubin,  which
could  imply  a  connection  between  liver  damage  in
general and GSt-a release into serum. In vitro data
demonstrated that the expression of GSt-a increases
in response to different drugs, though, the influence
of  immunosuppressive  agents  on  GSt-a expression
has not been tested so far [19]. However, in our study
GSt-a levels  of  the  recipients  with  good  outcome
were similar to those of donors, who did not receive
immunosuppressive drugs. taken together, high GSt-
a values in recipients with poor outcomes seem to re-
flect a higher cell death with impaired liver function.
It is well known that GSt-p is mainly expressed in
bile ducts and in oval cells [20] which partially consti-
tute the regenerative capacity of the liver [21]. usually,
raised serum levels of cholestatic enzymes are deemed
as  markers  for  advanced  fatty  liver  disease  [22]  or
damage to bile duct cells in chronic viral hepatitis [23].
but  as  we  have  previously  shown  in  patients  with
acute liver failure, gGt is significantly increased in pa-
tients  with  positive  outcome  after  acute  liver  failure
[24]. Massive cell injury in the liver is known to trigger
ductular proliferation involving mature cholangiocytes
and hepatocytes [25, 26]. It was also shown that an in-
crease in bile acids after partial hepatectomy is indica-
tive of liver regeneration [27, 28]. thus, cholestatic en-
zymes (such as gGt) may increase as a consequence of
elevated bile acids that are associated with prolifera-
tion in the course of liver regeneration. In our patient
cohort  we  found  a  significant  correlation  between
GSt-p and  gGt.  Regarding  the  overall  picture  of
GSt-p and  cholestatic  enzymes  as  gGt a  fast  and
short increase of these parameters in patient sera may
imply regenerative activity and thus a positive outcome
for  surgical  therapy.  In  contrast,  continuously  raised
serum levels still could be indicative for ongoing long
term liver damage and/or for a constant insufficient
regeneration. Graft survival was associated with higher
GSt-p values in recipients. the R1 recipients exhibit-
ed significantly lower plasma levels, below 50ﾵg/ml.
d1-patients were also found to have significantly low-
er GSt-p values before liver resection. the analysis of
individual  donor/recipient  pairs  revealed  that  low
GSt-p levels  in  donors  as  well  as  corresponding 
recipients at Pod 0 were associated with raised serum
alt and aSt and graft failure within 4 weeks post  -
operatively. In contrast to this no graft loss occurred
with GSt-p levels above 50ﾵg/ml in either donor or
recipient. 
the significantly lower GSt-p levels before ldlt
in the donor-recipient pairs, whose transplant failed,
indicate a link between this marker and graft failure.
However, GSt-p values of the d1 group increased at
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Table  2. correlation between liver function Parameters and GSt for donors and Recipients. Spearman-Rho correlation 
coefficients of GSt-a and GSt-p with alt, aSt, gGt and bilirubin as well as p-values of each correlation in donors and 
recipients.
ALT AST Bilirubin gGT
Donors
GST-a 0,378 (p<0.001) 0,399 (p<0.001) 0,323 (p<0.001) -0.001 (p=0.991)
GST-p -0.072 (p=0.414) -0.153 (p=0.082) -0.144 (p=0.099) 0.212 (p=0.017)
Recipients
GST-a 0.597 (p<0.001) 0.629 (p<0.001) 0.315 (p<0.001) -0.330 (p<0.001)
GST-p 0.69 (p=0.425) 0.114 (p=0.188) 0.05 (p=0.563) 0.307 (p<0.001)
6) Jochum_Umbruchvorlage  14.01.11  12:09  Seite 38an adequate rate and no significant differences to d2
were  detectable  during  the  post  transplant  period.
Strikingly,  the  aforementioned  postoperative  GSt-p
increase did not occur in the R1 group.
taken  together,  these  observations  suggest  that
higher levels of GSt-p reflect normal liver regenera-
tion.  Since  no  correlation  to  bilirubin  could  be  ob-
served, GSt-p may rather indicate a higher turnover
of oval cells and bile duct proliferation during liver re-
generation than cholestatic damage. from the present
data it is not yet possible to say if low GSt-p may
have a causal connection to the early graft loss or if
the low values are an additional consequence of liver
cell damage leading to graft failure. Some causal con-
nection is supported by the observation that only re-
cipients  whose  donors  exhibited  simultaneously  low
pretransplant  GSt-p values  developed  graft  failure.
Since the numbers of patients in our study is low and
comparable  animal  studies  are  lacking,  this  remains
speculative.
nevertheless,  our  data  indicate  that  higher  GSt-p
levels predict a favorable outcome and support an im-
portant  role  of  oval  cells  and  bile  duct  proliferation
during the process of liver regeneration in humans af-
ter ldlt. furthermore, our data suggest that low GSt-
p levels in donors and their recipients implicate a high-
er risk for graft failure and could therefore denote a pre  -
operative negative indicator for patients on waiting list
for deceased donor transplantation ori n preparation for
ldlt. further analysis of additional donor and recipi-
ent pairs in ldlt is warranted to specify limiting val-
ues for plasma GSt-p before and after transplantation. 
In conclusion the data at hand indicate a role for
GSt-a in ongoing liver damage while GSt-p seems
representative for regenerative capacity. both parame-
ters could may be  a complementary way to describe
or even predict the possible outcome of ldlt.
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